Clinical and in-vivo results conducted on a small group of ATTR patients suffering from polyneuropathy showed a durable inhibition of TTR gene expression ranging from 80%–90% after 28 days of receiving a single dose (Gillmore et al., 2021). The gene discussed is TTR; the disease is polyneuropathy.